FRAMINGHAM, Mass., Nov. 27 /PRNewswire-FirstCall/ -- StatSure Diagnostic Systems, Inc. announced the issuance in Japan and in India of additional international patents for its diagnostic testing platform, termed the “barrel” technology. StatSure’s technology is also protected by a US patent and is part of a licensed, FDA approved and CLIA waived product for HIV, currently being sold in the US and elsewhere. The barrel technology is an integrated, disposable device used to rapidly and safely collect, process and test patients in point-of care locations to screen for certain infectious diseases. Results can be read within minutes, without instrumentation and the kit may be stored without refrigeration for up to 24 months. Point-of- care markets include clinics, doctors’ office, emergency rooms and many other sites where results are needed quickly and safely.
The barrel-based product requires a tiny drop (~2.5 microliters) of whole blood, serum, or plasma and eliminates the need to separately handle, collect, and dispense a physiological specimen. Typically, the tip of the barrel touches a drop of fingertip blood, and though capillary action moves the specimen to the test strip inside the barrel, thereby minimizing the possibility of technician exposure to the potentially infected blood. A buffer vial sits atop the barrel forming a full kit with no other items needed. The test comes with an internal control to confirm that the test has been done correctly.
ABOUT STATSURE
StatSure Diagnostic Systems, Inc. is engaged in the development, manufacture and marketing of rapid immunoassay tests for the detection of sexually transmitted and other infectious diseases; in addition, the Company has developed and is marketing a product line of patented, oral- fluid collection devices. The Company’s proprietary platforms provide significant customer benefits and competitive advantages as compared to similar products that are currently available. Improved accuracy, operator convenience, and reduced risk of infection from collecting and handling specimens, have been engineered into SDS products. All of the company’s diagnostic tests are based on the same easy-to-use technology platform, thus facilitating the development of future products. Certain of these products are sold in the United States as well as internationally to various distributors for use in clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations.
Please visit our website at http://www.StatSure.com
FORWARD-LOOKING STATEMENTS This press release may contain forward-looking statements within the meaning of the federal securities laws. These statements reflect StatSure’s current views with respect to future events and are based on management’s current assumptions and information currently available. Actual results may differ materially due to numerous factors, including without limitation, the future demand for HIV testing products; our ability to successfully commercialize the products; the intensely competitive environment in the relevant markets and the risks and uncertainties described in periodic reports filed by StatSure with the Securities and Exchange Commission under the federal securities laws, including periodic reports on Form 10-Q or Form 10-QSB, as applicable, for the period ended June 30, 2007. StatSure undertakes no obligation to update any forward-looking statements contained herein.
CONTACT: Investor Relations, SDS, +1-508-872-2625
Web site: http://www.salv.com/
http://www.StatSure.com/
